Xin Ming Matthew Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Ming Matthew Zhou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Joel C. Sunshine
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
4 shared publications - Jordan J. Green
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA
2 shared publications - Kathryn M. Luly
Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications - Sachin S. Surwase
Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine, Baltimore, USA
2 shared publications - Stephany Y. Tzeng
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
2 shared publications - Anjali J. D'AMiano
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by Wiley in Advanced Science
Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models
Background & Aims : Primary liver cancer is the third leading cause of cancer death worldwide, and about 70% of hepatocellular carcinomas (HCCs) do not respond to systemic immunotherapies. Transarterial chemoembolization (TACE) remains standard treatment for intermediate‐stage HCC, but long‐term survival is poor. We aimed to develop a polymeric TACE‐like platform to sensitize liver cancer to checkpoint inhibitors by enabling sustained co‐delivery of panobinostat and IL‐12. Methods : Patient‐derived liver cancer organoids were used to screen drugs and identify panobinostat as a cytotoxic agent. We then formulated sustained‐release microparticles from anionic poly(lactic‐co‐glycolic acid) (PLGA) and cationic poly(beta‐amino ester) (PBAE) for combined delivery of panobinostat and IL‐12, and tested the system in three liver cancer models. Results : The microparticles achieved tumor‐specific retention and sustained release for two weeks following a single intratumoral or intrahepatic arterial injection. This led to tumor inhibition and prolonged survival in orthotopic liver cancer models. Mechanistically, treatment promoted tertiary lymphoid structure formation, increased infiltration of immune cells, and elevated pro‐inflammatory cytokines, triggering innate and adaptive antitumor immune responses. Conclusions : A PLGA/PBAE sustained‐release microparticle platform was successfully developed for TACE‐like co‐delivery of panobinostat and IL‐12. This combined chemoimmunotherapy strategy shows promise for overcoming immune suppression and improving liver cancer treatment.
- 24 August 2026
- Published by Wiley in Advanced Science
Open AccessSingle‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models
Background & Aims : Primary liver cancer is the third leading cause of cancer death worldwide, and about 70% of hepatocellular carcinomas (HCCs) do not respond to systemic immunotherapies. Transarterial chemoembolization (TACE) remains standard treatment for intermediate‐stage HCC, but long‐term survival is poor. We aimed to develop a polymeric TACE‐like platform to sensitize liver cancer to checkpoint inhibitors by enabling sustained co‐delivery of panobinostat and IL‐12. Methods : Patient‐derived liver cancer organoids were used to screen drugs and identify panobinostat as a cytotoxic agent. We then formulated sustained‐release microparticles from anionic poly(lactic‐co‐glycolic acid) (PLGA) and cationic poly(beta‐amino ester) (PBAE) for combined delivery of panobinostat and IL‐12, and tested the system in three liver cancer models. Results : The microparticles achieved tumor‐specific retention and sustained release for two weeks following a single intratumoral or intrahepatic arterial injection. This led to tumor inhibition and prolonged survival in orthotopic liver cancer models. Mechanistically, treatment promoted tertiary lymphoid structure formation, increased infiltration of immune cells, and elevated pro‐inflammatory cytokines, triggering innate and adaptive antitumor immune responses. Conclusions : A PLGA/PBAE sustained‐release microparticle platform was successfully developed for TACE‐like co‐delivery of panobinostat and IL‐12. This combined chemoimmunotherapy strategy shows promise for overcoming immune suppression and improving liver cancer treatment.
- Open Access
- 27 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012856
Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery
Introduction: An adaptive immune response to cancer requires three main signals: antigen presentation and recognition (“signal 1”), costimulation (“signal 2”), and secreted immunostimulatory cytokines (“signal 3”). Expression of these signals in tumors via non-viral gene delivery represents a promising strategy to reprogram the tumor microenvironment (TME) and prime antitumor immunity. Methods: We used modular polymeric poly(beta-amino ester)-based nanoparticles (NPs) to investigate codelivery of plasmids encoding signal 3s (interleukin (IL)-2, IL-12, IL-15, IL-23, IL-35, or granulocyte-macrophage colony-stimulating factor) and signal 2s (4-1BBL, CD80, CD86, or OX40L) to B16F10 melanoma tumors in vivo. Downstream immune responses and impact on the TME were assessed via flow cytometry and spatial proteomics using a 27-marker PhenoCycler panel. Results: Ex vivo flow cytometry and PhenoCycler tissue analysis revealed that multiple signal 2/3 NP combinations led to decreased tumor growth, increased immune-cell infiltration, and skewing of adaptive and innate populations towards immunostimulatory phenotypes with increased CD8 + T-cell and M1 macrophage infiltration. Signal 2/3 NPs also drove antigen presentation on tumor and antigen-presenting cells (APCs) (macrophages, dendritic cells), and led to induction of major histocompatibility complex class I and class II on melanoma cells. Evaluation of putative biomarkers of treatment response to signal 2/3 NP delivery demonstrated that multiple markers of an inflamed TME correlated negatively with tumor growth, with antigen presentation induction highly correlated with tumor size reduction. Spatial analysis on top-performing NP formulations demonstrated that immune cell populations entered the TME via both the tumor–stroma interface and intratumoral vessels; CD8 + T cells and proinflammatory M1 macrophages were brought into proximity. Furthermore, top NP formulations increased the density of intratumoral CD8 + -CD4 + -proinflammatory APC triads, which have been identified as key structures for immunotherapy-mediated clearance of solid tumors. Conclusions: These results demonstrate the utility of a modular NP design for systematic screening of signal 2/3 delivery to melanoma in vivo and highlight the benefit of in-depth profiling via spatial proteomics to evaluate local antitumor immune responses. The results provide insight into the mechanisms underpinning this therapeutic reprogramming strategy, emphasizing the relationship between signal 2/3 NPs and their ability to drive signal 1 for productive antitumor responses in vivo.
- 27 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012856
Open AccessReprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery
Introduction: An adaptive immune response to cancer requires three main signals: antigen presentation and recognition (“signal 1”), costimulation (“signal 2”), and secreted immunostimulatory cytokines (“signal 3”). Expression of these signals in tumors via non-viral gene delivery represents a promising strategy to reprogram the tumor microenvironment (TME) and prime antitumor immunity. Methods: We used modular polymeric poly(beta-amino ester)-based nanoparticles (NPs) to investigate codelivery of plasmids encoding signal 3s (interleukin (IL)-2, IL-12, IL-15, IL-23, IL-35, or granulocyte-macrophage colony-stimulating factor) and signal 2s (4-1BBL, CD80, CD86, or OX40L) to B16F10 melanoma tumors in vivo. Downstream immune responses and impact on the TME were assessed via flow cytometry and spatial proteomics using a 27-marker PhenoCycler panel. Results: Ex vivo flow cytometry and PhenoCycler tissue analysis revealed that multiple signal 2/3 NP combinations led to decreased tumor growth, increased immune-cell infiltration, and skewing of adaptive and innate populations towards immunostimulatory phenotypes with increased CD8 + T-cell and M1 macrophage infiltration. Signal 2/3 NPs also drove antigen presentation on tumor and antigen-presenting cells (APCs) (macrophages, dendritic cells), and led to induction of major histocompatibility complex class I and class II on melanoma cells. Evaluation of putative biomarkers of treatment response to signal 2/3 NP delivery demonstrated that multiple markers of an inflamed TME correlated negatively with tumor growth, with antigen presentation induction highly correlated with tumor size reduction. Spatial analysis on top-performing NP formulations demonstrated that immune cell populations entered the TME via both the tumor–stroma interface and intratumoral vessels; CD8 + T cells and proinflammatory M1 macrophages were brought into proximity. Furthermore, top NP formulations increased the density of intratumoral CD8 + -CD4 + -proinflammatory APC triads, which have been identified as key structures for immunotherapy-mediated clearance of solid tumors. Conclusions: These results demonstrate the utility of a modular NP design for systematic screening of signal 2/3 delivery to melanoma in vivo and highlight the benefit of in-depth profiling via spatial proteomics to evaluate local antitumor immune responses. The results provide insight into the mechanisms underpinning this therapeutic reprogramming strategy, emphasizing the relationship between signal 2/3 NPs and their ability to drive signal 1 for productive antitumor responses in vivo.
- 8 October 2025
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 44 (4) , 1-20
Spatial proteomics for investigating solid tumor resistance mechanisms
Spatial proteomics technologies have been pivotal in profiling tumor immune microenvironments at single-cell resolution, advancing our understanding of cancer biology, identifying key cell populations in solid tumors, and predicting treatment responses. Although immune checkpoint and molecular inhibitors have revolutionized cancer care, resistance mechanisms remain a major therapeutic challenge that hinder productive responses in a notable fraction of cancer patients. In this review, we outline current spatial proteomics and computational analysis tools for studying the tumor immune microenvironment and discuss how spatial proteomics techniques have helped elucidate cancer resistance mechanisms across multiple tumor types. In this process, we highlight the importance of investigating immunosuppressive cell populations that can mediate cancer resistance, specifically with regard to their localization, protein signatures, and surrounding interactions. Finally, we provide a look ahead at future applications of artificial intelligence/machine learning and multi-omics approaches that will help further propel our understanding of cancer resistance mechanisms through spatial biology research.
- 8 October 2025
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 44 (4) , 1-20
Spatial proteomics for investigating solid tumor resistance mechanisms
Spatial proteomics technologies have been pivotal in profiling tumor immune microenvironments at single-cell resolution, advancing our understanding of cancer biology, identifying key cell populations in solid tumors, and predicting treatment responses. Although immune checkpoint and molecular inhibitors have revolutionized cancer care, resistance mechanisms remain a major therapeutic challenge that hinder productive responses in a notable fraction of cancer patients. In this review, we outline current spatial proteomics and computational analysis tools for studying the tumor immune microenvironment and discuss how spatial proteomics techniques have helped elucidate cancer resistance mechanisms across multiple tumor types. In this process, we highlight the importance of investigating immunosuppressive cell populations that can mediate cancer resistance, specifically with regard to their localization, protein signatures, and surrounding interactions. Finally, we provide a look ahead at future applications of artificial intelligence/machine learning and multi-omics approaches that will help further propel our understanding of cancer resistance mechanisms through spatial biology research.
- 28 October 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (1) , 102165
Highly Multiplexed Immunofluorescence PhenoCycler Panel for Murine Formalin-Fixed Paraffin-Embedded Tissues Yields Insight Into Tumor Microenvironment Immunoengineering
- 28 October 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (1) , 102165
Highly Multiplexed Immunofluorescence PhenoCycler Panel for Murine Formalin-Fixed Paraffin-Embedded Tissues Yields Insight Into Tumor Microenvironment Immunoengineering